Bangalore-based biotech company Biocon Ltd revealed that it will be joining hands with CytoSorbents Corporation that will see it gain exclusive commercialization rights for its sepsis treatment therapy, CytoSorb in India and other emerging markets. Biocon Managing Director Kiran Mazumdar Shaw revealed that CytoSorb has been proved to be a 'first-in-class' therapy that is effective in treating sepsis patients. While the financial details of the deal were not ...
via Medindia Health News More READ
No comments:
Post a Comment